IONIS PHARMACEUTICALS INC — Director's Dealing 2020

Jun 19, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2020-06-17

Reporting Person: CROOKE STANLEY T (Director, Exec Chairman of the Board)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-17	Common Stock	S	15000	$57.9014	Disposed	26935	Direct
2020-06-17	Common Stock	S	2000	$58.25	Disposed	3581	Indirect
2020-06-19	Common Stock	S	10000	$58.325	Disposed	16935	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	700391	Indirect

Footnotes

F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.

F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.59 to $58.36, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4

F3: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on January 2, 2020.

F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.25 to $58.40, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) of this Form 4